Lixte Biotechnology Holdings, Inc.

DB:8640 Stock Report

Market Cap: €5.2m

Lixte Biotechnology Holdings Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 8640?
Owner TypeNumber of SharesOwnership Percentage
Private Companies64,5812.87%
Institutions268,69011.9%
Individual Insiders884,19239.3%
General Public1,031,82745.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.1%.

Top Shareholders

Top 25 shareholders own 54.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.8%
John Kovach
287,352€669.5k0%no data
11%
Ethos Financial Group, LLC
248,084€578.0k900%0.2%
4.63%
Hung Tak Ho
104,211€242.8k0%no data
3.58%
David Sterling
80,545€187.7k0%no data
2.72%
Eric Forman
61,071€142.3k0%no data
2.26%
Arthur Riggs
50,917€118.6k0%no data
2.26%
Jane Riggs
50,917€118.6k0%no data
2.21%
Robert Greenberg
49,715€115.8k0%no data
2.21%
Susan Greenberg
49,715€115.8k0%no data
1.85%
Lalit Bahl
41,667€97.1k0%no data
1.85%
Kavita Kinra
41,667€97.1k0%no data
1.27%
Schwartzberg Trust
28,573€66.6k0%no data
0.67%
René Bernards
15,000€35.0k0%no data
0.63%
Glenn Krinsky
14,167€33.0k0%no data
0.63%
Glenn Krinsky
14,166€33.0k0%no data
0.45%
Geode Capital Management, LLC
10,119€23.6k-0.01%no data
0.4%
Amanda Sterling Trust
9,000€21.0k0%no data
0.4%
Charles Sterling Trust
9,000€21.0k0%no data
0.4%
Daniel Sterling Trust
9,000€21.0k0%no data
0.4%
Savannah Sterling Trust
9,000€21.0k0%no data
0.39%
Cole Forman
8,708€20.3k0%no data
0.33%
Stephan Forman
7,481€17.4k0%no data
0.32%
Morgan Stanley & Co. International Plc Investment Account
7,106€16.6k0.01%no data
0.23%
Yun Yen
5,263€12.3k0%no data
0.15%
The Vanguard Group, Inc.
3,274€7.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/02 06:20
End of Day Share Price 2023/06/05 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lixte Biotechnology Holdings, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution